Please complete the applicable rows in the following table. Monetary amounts are on an annual basis.

Similar documents
DCRI COMMERCIAL RELATIONSHIPS TRACKING FORM

DCRI COMMERCIAL RELATIONSHIPS TRACKING FORM

(3) Educational Activities or Lectures for this Company Generates Revenue for Duke $5K $25K >$25K

Please complete the applicable rows in the following table. Monetary amounts are on an annual basis.

DCRI COMMERCIAL RELATIONSHIPS TRACKING FORM

DCRI COMMERCIAL RELATIONSHIPS TRACKING FORM

DCRI COMMERCIAL RELATIONSHIPS TRACKING FORM

Please complete the applicable rows in the following table. Monetary amounts are on an annual basis.

Method of Declaration. Hospitality/Interest/Sponsorship

Ownership/ Partnership/ Principal. None None None Lantheus Medical Imaging (DSMB) NIH (DSMB)* None None None None None None

GLOBAL MARKETS AND TECHNOLOGIES FOR ADVANCED DRUG DELIVERY SYSTEMS

Early Valuation. Company Portfolio

THE CORPORATE REPUTATION OF PHARMA THE PATIENT PERSPECTIVE IN 2015 (EASTERN-EUROPE EDITION)

Previous Attendees List:

TRENDS IN IP DISPUTES

Associate Director. Biomarker Operations Lead. Business Development & Strategic Alliances. Business Development Executive

2017 IPCC Attendee List

HEARTS/NASCI/RSNA/SAIP/SCAI/SCCT/SCMR/SNMMI 2014 Health Policy Statement on Use of Noninvasive Cardiovascular Imaging

Monetizing Early-Stage R&D Assets. March 18, 2015

Committee Member Employment Consultant Speaker s Bureau Ownership/ Partnership / Principal. Expert Witness

Reinventing Invention: Advancing Collaboration for Sustainable Bioscience R&D

Other appointments: Chairman of the Advisory Committee of Zentiva Group, Industrial Advisor EQT.

Born Ph.D. from Karolinska Institutet in Stockholm. Board member since 2016.

Institutional, Organizational, or Other Financial. Ownership/ Partnership/Principa. Speakers Bureau. Reviewer Representation Employment Consultant

State of Licensing 2011 Update

Cardiac Safety Research Consortium: A Decade of CSRC. Mitchell W. Krucoff, MD, FACC

DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS

The 2011 EU industrial R&D investment SCOREBOARD

Life Sciences CONFERENCE SERIES. Business Information in a Global Context LIFE SCIENCES IP PORTFOLIO. Business Development Pack

Mixed Signals: Understanding the Outlook for Pharma R&D Spending Through

2018 AATS/ACC/SCAI/STS

Innovation and the Changing Practice of Medicine

Heart Valve Summit: Medical, Surgical and Interventional Decision Making

Appendix 1. Participants in the ACCF/AHA Consensus Conference on Professionalism and Ethics

European companies outpace American counterparts in R&D investment growth for the first time in five years

2018 Building Better Business Connections (3BC) Event Optimizing the Role of Male Champions

ACC.13 Committee Disclosures Page 1 of 9

SPC developments in Europe AIPPI Marjan Noor Simmons & Simmons

ACC.18 ABSTRACT REVIEWERS Disclosures

ACC.17 Program Committee Disclosures of Relationships With Industry Disclosures

Baxter 2007 Investor Conference March 14, 2007

HESI Annual Meeting January 19, Welcome!!!! Meeting of the. HESI Assembly of Members. Dr. James MacDonald President of HESI 01/19/09

1. Your Identity. Photo. Treasurer. Application for the following position in the EHRA Board: Title: Prof, MD. Family Name(s): Pürerfellner

Corporate Compliance & Transparency

International Strategy Development Training: a personal strategic development workshop for Life Sciences Executives of SMEs

LIGHTHOUSE. The Science of Pharmaceutical Manufacturing

2018 IPCC Attendee List

SZF Associates. SZF is an issues-oriented, evidence-based market research and consulting firm serving the pharmaceutical and biotech industry.

Peter Forman President & CEO South Shore Chamber of Commerce

MARKUSH FOR PATENT ANALYSIS. Steve Hajkowski ChemAxon UGM Budapest 2013

on the Anne Berberi, formerly Product Manager, Diabetes, at Bristol-Myers Squibb, has been appointed Senior Brand Manager, HCV, at AbbVie.

Management Team. Bruce C. Cozadd Chairman and Chief Executive Officer

NOTICE OF ANNUAL GENERAL MEETING. Thursday 30 March 2017 at am. H. Lundbeck A/S, Ottiliavej 9, DK-2500 Valby

Women leaders transforming the future through gender partnership

Healthcare and Life Sciences Group MERGERS & ACQUISITIONS

BREAKTHROUGH CONVENTION SUMMARY JUNE SAN DIEGO CONVENTION.BIO.ORG #BIO2017

PROTECT Project. Joanna Groves Chief Executive Officer 27 April 2010 EFPIA Patient Think-Tank Brussels, Belgium

2018 Annual Liver Meeting November 9-13, 2018 San Francisco, CA

Researched Medicines Industry Association of New Zealand Incorporated

IP for Development Indian Approach

The 2010 EU industrial R&D investment SCOREBOARD

TRANSFORMING THE FUTURE

Officer Director etc. Ownership Partnership Principal. Speaker's Bureau

March 20, The Honorable Dianne Feinstein United State Senate 331 Hart Office Building Washington, DC Dear Senator Feinstein:

TODAY LETTER DATED

Sanofi Announces Changes to Executive Committee Aligned to its Strategic Roadmap 2020

The importance of transnational corporations in research and development activities in the world

Healthcare and Life Sciences Group MERGERS & ACQUISITIONS

This report is prepared by:

Disclosures of Relevant Financial Relationships

Form FI. Management s Discussion and Analysis of Results of Operations and Financial condition for the six months ended April 30, 2007.

VALUE IN HEALTH 20 (2017) A384 A397

UBS Pathfinders Trust, Treasury and Growth Stock Series 23

PwC Deals $42B. Global Pharma & Life Sciences Deals Insights Q Update

BOARD OF DIRECTORS. PETER WEHRLY Chair

European Patent Reform Forum USA December , New York

Reference List Cha, Myoung., and Theresa Lorriman. February Why Pharma megamergers work. McKinsey&Company Our insights. Ward, Andrew.

We Work For Health Champions Awards Class of AstraZeneca: John McCarthy Vice President, Commercial Operations

HEALTHCARE TRANSACTIONS

New Rhein concludes successful investment in Chase Pharmaceuticals via sale to Allergan

Gilead Sciences. Very interesting in all areas. COMPANY Gilead Sciences Inc. INDUSTRY Biotechnology TYPE Public Company TICKER NasdaqGS:GILD

RICHARD BUTLAND Director

Skystar Bio-Pharmaceutical Co SKBI

SPONSORSHIP OPPORTUNITIES. Engage With Policymakers Connect With Biomedical Leaders Increase Your Corporate Visibility

Vanderbilt University - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Johnson & Johnson (JNJ) - Medical Equipment - Deals and Alliances Profile

30th Annual Oncology Nurses Symposium

Omeros Raises More Than $63 Million in Financing

Toward Clarity on Transparency. Conclusions Paper. An evolution in thinking and action about sharing patient-level clinical trial data

Be A Part of the Dynamic Healthcare Industry

Transforming the right molecules into the best medicines TM

Committee Disclosures Page 1 of 12

Presentation to Medicon Valley Alliance Crescendo Conference. Frank Yu Founder, CEO & CIO Ally Bridge Group Themes Investment Partners

Nektar Therapeutics (NKTR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

SPONSORSHIP OPPORTUNITIES ADVANCING CALIFORNIA BIOMEDICAL RESEARCH AND INNOVATION *BRAND RECOGNITION * MARKETING OPPORTUNITIES * NETWORKING * ACCESS*

The Future of Genomic Medicine X Thursday, March 2 Friday, March 3, 2017 Scripps Seaside Forum La Jolla, California. Exhibitor Prospectus

Skystar Bio-Pharmaceutical Co SKBI

Jay Ash Secretary of Housing & Economic Development, Commonwealth of Massachusetts

LIGAND PHARMACEUTICALS INCORPORATED (Exact Name of Registrant as Specified in Its Charter)

Trends at the frontier in Corporate R&D in the digital era

Transcription:

DCRI COMMERCIAL RELATIONSHIPS TRACKING FORM Year(s): 2015 Name: Patrick Pun, MD Title: Asasistant Professor of Medicine Address: DCRI Please complete the applicable rows in the following table. Monetary amounts are on an annual basis. : (1) A Research Grant or Contract from this Partially Supports My University Salary (2) A Research Grant or Contract from this Supports My Research Projects (3) Educational Activities or Lectures for this Generates Revenue for Duke <$5K $5K $25K >$25K (4) Consulting or Other Services (Including CME) for this Generates Personal Income <$5K $5K $25K (5) Consulting or Other non-cme Services for this Generates Personal Income >$25K <$5K $5K $25K (6) I Receive Significant Personal Royalties from this >$25K <$5 (7) I Have Equity in this K >$5K/1% Abbott Laboratories Abiomed Acerta Pharma Achillion Acorda Therapeutics, Inc Aires Akili Interactive Labs Alcobra Amgen, Amylin, ARCA Biopharma Ardea Biosciences, Armetheon Inc AstraZeneca page 1 of 7; 10/01/2012

Atentiv Inc Baseline Study LLC Baxalta Bayer US (Bayer AG/Bayer in Japan subsidiaries) Beckman Research Institiute Bellerophon Therapeutics Biogen Biogen Idec In Biomarin Biosensors International Group Ltd BioStealth Inc Boehringer Ingelheim Boston Scientific Bristol Myers Squibb Burroughs Welcome Fund Cardio3 Bioscience CardioDx, Cardiovascular Systems, Cempra, Cerenova, LLC CPC Clinical Research CSL Group 2 of 7;10/01/2010

CSL Limited Cubist Daiichi Sankyo Co. Limited Deloitte Consulting LLP Dr. Reddy's Laboratories LTD Duke Clinical Research Institute Duke Neurology Imaging Lab Durata Therapeutics Edwards Lifesciences Elesvier Eli Lilly & Evalve, Inc Exelixis, F Hoffmann-La Roche Ltd Ferring Genentech General Electric General Electric Healthcare Genetic Alliance Genzyme Gilead Sciences, Glaxo SmithKline (GSK) Grifols 3 of 7;10/01/2010

Harvard Pilgrim Health Care HeartFlow Hologic, Humacyte, Inc Immuron Ltd Janssen Pharmaceutica Products, L.P. Janssen Research and Development, LLC Janssen Scientific Affairs, LLB Johnson & Johnson Johnson & Johnson Research & Development LadeRX Luitpold, MAQUET Cardiovascular LLC (formerly Boston Scientific Cardiac & Vascular) Marinus Inc Medical Education Solutions Group MedImmune Inc Medscape, LLC Medtronic PLC 4 of 7;10/01/2010

Medtronic Vascular, (formerly Medtronic AVE) Merck & Co., Inc Merck Sharp & Dohme I.A. MyoKardia Inc Novartis Consumer Health Inc Novartis Novavax Inc Ophthotech OrbusNeich Otsuka America Oxygen Biotherapeutics (Formerly SBI) Pfizer Popluation Health Research Institute Portola Procyrion Inc Reflexion Health Regeneron, Research Triangle Institute ResMed RespireRX 5 of 7;10/01/2010

Roche Diagnostics Roche Diagnostics Corp Roche Group Sanofi-Aventis Shionogi Inc Society of Thoracic Surgeons Stealth Peptides Summit Swedish Orphan Biovitrum AB Tacere Therapeutics Taiwanj Ltg The Medicines Theravance Biopharma Thrombosis Research Institute Tokalas Inc University of Michigan Verily Life Sciences Zimmer Biomet Holdings Inc Relypsa x 6 of 7;10/01/2010

Column Explanations: (1) Funding is provided for my effort in research grants or contracts for multi-center projects in which I serve as either the Chairman, Co-Chairman, Executive or Steering Committee member or I am involved as a DCRI faculty leader for specific aspects in a project. A check in this column denotes that I am involved in such a research contract. Payments for the work performed for these contracts are made to the University. A portion of my salary as a faculty member, representative of % effort on the project, is supported by these funds. (2) A research grant from this company supports the expenses associated with projects in the DUHS that are under my direction. (3) I provide educational activities or deliver occasional lectures that generate revenue from this company. All revenues from these activities are paid to the University. None of it is taken for personal income. The three columns represent annual payments of more than $5,000, between $5,000 and $25,000, and in excess of $25,000 per year from this company. (4) I receive personal income outside of my University salary for consulting or other services (Including CME) from this company. The three columns represent annual payments of more than $5,000, between $5,000 and $25,000, and in excess of $25,000 per year from this company. (5) I receive personal income outside of my University salary for consulting or other non-cme services from this company. The three columns represent annual payments of more than $5,000, between $5,000 and $25,000, and in excess of $25,000 per year from this company. (6) I personally receive royalties in excess of $5,000 per year from this company. (7) I, or an immediate member of my family, have equity (with shareholder voting privileges) in this company of either > $5,000 or > 1%. 7 of 7;10/01/2010